| Non-viral ex vivo genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9 S Byambaa, H Uosaki, T Ohmori, H Hara, H Endo, O Nureki, Y Hanazono Molecular Therapy-Methods & Clinical Development, 2021 | 9 | 2021 |
| Generation of novel Il2rg-knockout mice with clustered regularly interspaced short palindromic repeats (CRISPR) and Cas9 S Byambaa, H Uosaki, H Hara, Y Nagao, T Abe, H Shibata, O Nureki, ... Experimental Animals 69 (2), 189-198, 2020 | 7 | 2020 |
| Nonviral Ex Vivo Genome Editing in Mouse Bona Fide Hematopoietic Stem Cells with CRISPR/Cas9 H Hara, N Munkh-Erdene, S Byambaa, Y Hanazono Genome Editing in Animals: Methods and Protocols, 213-221, 2023 | | 2023 |
| Cure of X-SCID Mice after Ex Vivo Non-Viral Genome-Editing Therapy of Hematopoietic Stem Cells S Byambaa, H Uosaki, H Hara, H Shibata, T Abe, H Hayakawa, Y Nagao, ... MOLECULAR THERAPY 27 (4), 394-395, 2019 | | 2019 |
| Resistance of Mouse Hematopoietic Stem and Progenitor Cells to the Genome-Editing with Cas9 S Byambaa, H Uosaki, H Hara, T Abe, Y Nagao, O Nureki, T Ohmori, ... MOLECULAR THERAPY 25 (5), 93-93, 2017 | | 2017 |
